Apply to trial NCT04864054

A few quick questions so the study team can decide if you might be a fit.

RecruitingBiological intervention

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening